MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Biogen Inc

Отворен

СекторЗдравеопазване

118.15 -0.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

117.21

Максимум

119.98

Ключови измерители

By Trading Economics

Приходи

-122M

267M

Продажби

-15M

2.5B

P/E

Средно за сектора

10.42

57.333

EPS

3.44

Марж на печалбата

10.865

Служители

7,605

EBITDA

-158M

536M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+51.84% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-4.2B

17B

Предишно отваряне

119.03

Предишно затваряне

118.15

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Biogen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.09.2024 г., 11:00 ч. UTC

Топ новини

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29.05.2024 г., 15:56 ч. UTC

Печалби
Придобивния, сливания и поглъщания

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Biogen Inc Прогноза

Ценова цел

By TipRanks

51.84% нагоре

12-месечна прогноза

Среден 181.46 USD  51.84%

Висок 265 USD

Нисък 121 USD

Според 29 анализатори от Wall Street, предложили 12-месечна ценова цел за Biogen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

29 ratings

14

Купи

15

Задържане

0

Продай

Техническа оценка

By Trading Central

118.83 / 119.99Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.